Ceera Investments LLC Boosts Holdings in Pfizer Inc. (NYSE:PFE)

Ceera Investments LLC raised its holdings in Pfizer Inc. (NYSE:PFE) by 13.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 52,051 shares of the biopharmaceutical company’s stock after acquiring an additional 6,065 shares during the period. Ceera Investments LLC’s holdings in Pfizer were worth $1,506,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Olistico Wealth LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth about $25,000. MFA Wealth Advisors LLC purchased a new stake in shares of Pfizer during the 2nd quarter worth about $29,000. Gladius Capital Management LP boosted its holdings in Pfizer by 102.8% in the 3rd quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock worth $30,000 after acquiring an additional 38,015 shares during the period. Quarry LP purchased a new position in Pfizer in the 2nd quarter worth approximately $31,000. Finally, Financial Connections Group Inc. purchased a new position in Pfizer in the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have weighed in on PFE. Sanford C. Bernstein began coverage on Pfizer in a report on Thursday, October 17th. They issued a “market perform” rating and a $32.00 price target for the company. Evercore ISI upgraded Pfizer to a “strong-buy” rating in a report on Wednesday, October 30th. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 31st. Wolfe Research assumed coverage on Pfizer in a report on Friday. They issued an “underperform” rating and a $25.00 price target for the company. Finally, Barclays upped their target price on Pfizer from $30.00 to $32.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. One investment analyst has rated the stock with a sell rating, eight have given a hold rating, five have assigned a buy rating and three have issued a strong buy rating to the stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $32.92.

Pfizer Trading Down 4.7 %

NYSE:PFE opened at $24.80 on Friday. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54. The stock has a market cap of $140.54 billion, a price-to-earnings ratio of 33.51, a PEG ratio of 0.79 and a beta of 0.67. The business has a fifty day moving average of $28.64 and a 200-day moving average of $28.66. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, October 29th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.64 by $0.42. Pfizer had a return on equity of 16.28% and a net margin of 7.07%. The company had revenue of $17.70 billion during the quarter, compared to analysts’ expectations of $14.92 billion. During the same quarter in the prior year, the business posted ($0.17) earnings per share. The company’s revenue for the quarter was up 31.2% compared to the same quarter last year. Equities analysts predict that Pfizer Inc. will post 2.96 earnings per share for the current year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Investors of record on Friday, November 8th will be paid a dividend of $0.42 per share. The ex-dividend date is Friday, November 8th. This represents a $1.68 annualized dividend and a yield of 6.77%. Pfizer’s dividend payout ratio is currently 227.03%.

Insider Activity at Pfizer

In other Pfizer news, Director Scott Gottlieb acquired 1,000 shares of Pfizer stock in a transaction that occurred on Wednesday, October 30th. The stock was purchased at an average cost of $28.24 per share, with a total value of $28,240.00. Following the purchase, the director now owns 10,000 shares in the company, valued at approximately $282,400. The trade was a 11.11 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 0.06% of the company’s stock.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.